Kalyan Roy: The Oxygen Delivery Paradox in Polycythaemia Vera
Kalyan Roy, Transfusion Medicine Specialist at Square Hospitals LTD, shared a post on LinkedIn:
“The Oxygen Delivery Paradox in Polycythaemia Vera (PV)
At first glance, a higher hematocrit appears beneficial because it increases red blood cell mass and total oxygen content. However, the physiology is more complex.
What Happens When Hematocrit Rises?
- Increased hematocrit or increased red blood cell mass
- Leads to Increased Blood Viscosity
- Which leads to Reduced microcirculatory blood flow
- Which results in Reduced tissue perfusion and oxygen delivery
- Leading to Increased endothelial activation
- Which increases The risk of arterial and venous thrombosis
Key Message
More RBCs mean More Oxygen Content
But not necessarily better oxygen delivery
As blood becomes more viscous, capillary flow and tissue perfusion decline. The result is a paradox where oxygen content rises while oxygen delivery to tissues may actually fall.
Clinical Relevance in PV
- Hyperviscosity is a major driver of symptoms and thrombosis.
- Maintaining hematocrit lower than 45% improves microcirculatory flow and reduces thrombotic complications.
- The goal of treatment is not simply to lower hematocrit, but to optimize tissue oxygen delivery and vascular health.
In Polycythaemia Vera, the problem is often not oxygen carrying capacity – it is impaired oxygen delivery due to hyperviscosity.”
Find more posts featuring Kalyan Roy on Hemostasis Today.
-
Aug 9, 2026, 09:16Preparing for Gene Therapy Starts with Understanding Immunity – WFH
-
Aug 9, 2026, 08:46Christina Pohlman: Uncovering the Autoantibodies Behind APS
-
Aug 9, 2026, 08:39Alejandro González Veliz: The Future of Cardiogenic Shock Lies in Precision Medicine
-
Aug 9, 2026, 08:29Heba Youssef: Off-Label Doesn’t Mean Off-Guidelines
-
Aug 9, 2026, 08:18Fawaz AlOtaibi: Why Experts Are Challenging the New Stroke Guideline
-
Aug 9, 2026, 08:08Jason Carney: Addressing the National Blood Shortage Through AI-Driven Patient Blood Management
-
Aug 9, 2026, 07:54Hamdy Alkady: FDA Approves the First Oral PCSK9 Inhibitor
-
Aug 9, 2026, 07:51Mostafa Hammam: Antibody Panels in Blood Bank Feeling Like a Chaotic Puzzle? Here is How to Master the Grid
-
Aug 9, 2026, 07:32Heghine Khachatryan: Less Frequent INR Monitoring – Does It Necessarily Mean Poorer Anticoagulation Control?